Yttrium-90 is an isotope of yttrium with medical significance [3] . Yttrium-90 plays an important role in the radionuclide therapy of cancer [4] .
| Yttrium-90 | |||||
|---|---|---|---|---|---|
| Name, symbol | Yttrium-90, 90 Y | ||||
| Neutrons | 51 | ||||
| Nuclide properties | |||||
| Half life | 64 hours | ||||
| Decay products | |||||
| |||||
Content
- 1 Decay
- 2 Getting
- 3 Clinical application
- 4 See also
- 5 notes
- 6 References
Decay
Yttrium-90 undergoes β - decay into zirconium-90 with a half-life of 64.1 hours [5] , a decay energy of 2.28 MeV [1] Emission of 0.01% 1.7 MeV [6] photons also occurs.
Getting
Yttrium-90 can be obtained by irradiating natural 89 Y neutrons in a reactor according to the scheme 89 Y (n, gamma) → 90 Y. [7] However, the low cross section of this reaction does not allow one to obtain a preparation with high activity.
Yttrium-90 is the decay product of strontium-90 , which is present in the decay chains of uranium with a yield of about 5%. [8] [9] However, direct chemical evolution of 90 Y from the fission products of uranium pollutes it with other yttrium isotopes, for example, 91 Y. Therefore, 90 Sr is chemically isolated from the decay products of uranium, maintained for 90 Y to be produced and chemically isolated. To simplify the process, special 90 Sr → 90 Y isotope generators are created, from which the target isotope is chemically washed out as it accumulates. [7]
Clinical application
90 Y plays an important role in the treatment of hepatic cell carcinoma, as well as other types of cancer. Interventional radiotherapists perform transarterial radioembolization of the tumor with microspheres containing 90 Y. [10] This procedure leads to a significant increase in the progression time in patients with hepatic cell carcinoma, [11] has a small number of side effects and, when compared with other treatment methods, is more improves the quality of life of patients. [12]
In Russia, trials of drugs based on 90 Y are being conducted. [13]
See also
- Yttrium Isotopes
Notes
- ↑ 1 2 Table of Isotopes decay data . The Lund / LBNL Nuclear Data Search (February 1999). Date of treatment October 23, 2012.
- ↑ NuDat - 2.6
- ↑ DeVita, Hellman, and Rosenberg's cancer: principles & practice of oncology . - Lippincott Williams & Wilkins, April 1, 2008. - P. 2507–. - ISBN 978-0-7817-7207-5 .
- ↑ Arkadiy Kheyfits. Yttrium-90 Radioembolization . Radiology Today (October 2010). Date of treatment October 23, 2012.
- ↑ Y-90 Handling Precautions (link not available) . Date of treatment July 15, 2015. Archived March 4, 2016.
- ↑ (2009) " Optimization of Yttrium-90 Bremsstrahlung Imaging with Monte Carlo Simulations " in 4th European Conference of the International Federation for Medical and Biological Engineering . 22 : 500-504. Retrieved October 21, 2013 .
- ↑ 1 2 Yttrium radioactive
- ↑ Strontium | Radiation Protection | US EPA . EPA (April 24, 2012). Date of treatment October 23, 2012.
- ↑ PNNL: Isotope Sciences Program - Yttrium-90 Production (Link not available) . PNNL (February 2012). Date of treatment October 23, 2012. Archived July 23, 2012.
- ↑ Kallini JR, Gabr A., Salem R., Lewandowski RJ. Trans-arterial Radioembolization with Yttrium-90 for the Treatment of Hepatocellular Carcinoma (Eng.) // Adv Ther. : journal. - 2016 .-- April 2.
- ↑ Salem R., Gordon AC, Mouli S., Hickey R., Kallini J., et al. Y90 Radioembolization Significantly Prolongs Time to Progression Compared With Chemoembolization in Patients With Hepatocellular Carcinoma (English) // Gastroenterology: journal. - 2016 .-- 26 August ( vol. 151 ). - P. 1155-1163.e2 . - DOI : 10.1053 / j.gastro.2016.08.08.029 . - PMID 27575820 .
- ↑ Salem, R. Gilbertsen, M. Butt, Z. Memon, K. Vouche, M. Hickey, R. Baker, T. Abecassis, MM Atassi, R. Riaz, A. Cella, D. Burns, JL Ganger, D Benson, AB, 3rd Mulcahy, MF Kulik, L. Lewandowski, R. Increased quality of life among hepatocellular carcinoma patients treated with radioembolization, compared with chemoembolization (English) // Clin Gastroenterol Hepatol : journal. - 2013 .-- Vol. 11 , no. 10 . - P. 1358-1365.e1 . - DOI : 10.1016 / j.cgh.2013.04.0.028 .
- ↑ Russian drug for the treatment of liver cancer based on the yttrium-90 isotope is being prepared for CI